The effect of selective alpha-1 receptor antagonist on arterial stiffness parameters in patients with benign prostatic hyperplasia

Abstract

Objective: Non-selective adrenergic alpha-1 antagonists have been shown to reduce arterial stiffness. Our aim is to assess the effects of a selective adrenergic alpha-1 antagonist on arterial stiffness, namely silodosin. Patients and Methods: This prospective study was carried out on 20 patients with recently diagnosed benign prostatic hyperplasia (BPH). International Prostate Symptom Score (IPSS) calculation, arterial stiffness test with an oscillometric device, and uroflowmetry were performed prior to the planned silodosin medical treatment. After initial assessment, patients were given 8 mg of silodosin daily. Initial tests and calculations were repeated after 1 month of follow-up. Comparisons between baseline and control data were performed using the paired sample t-test and the Wilcoxon signed-rank test for normally and non-normally distributed data, respectively. Results: There was a significant reduction in the IPSS of patients after silodosin treatment (p < 0.001). There were statistically insignificant reductions in arterial stiffness and systolic blood pressure, and an increase in maximum flow rate (p = 0.314, p = 0.608, and p = 0.053, respectively). Conclusion: Silodosin is an effective drug to relieve BPH symptoms but does not have a statistically significant effect on neither blood pressure nor arterial stiffness.

Keywords

• Adrenergic alpha-1 receptor antagonists
• Arterial stiffness
• Benign prostate hyperplasia
• Silodosin

References

1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005;7 Suppl 9(Suppl 9):S3-s14.
2. Egan KB. The Epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: Prevalence and incident rates. Urol Clin North Am 2016;43:289-97. doi:10.1016/j.ucl.2016.04.001
3. Bishr M, Boehm K, Trudeau V, et al. Medical management of benign prostatic hyperplasia: Results from a population-based study. Can Urol Assoc J 2016;10:55-9. doi:10.5489/cuaj.3058
4. Dhingra N, Bhagwat D. Benign prostatic hyperplasia: An overview of existing treatment. Indian J Pharmacol 2011;43:6- 12. doi:10.4103/0253-7613.75657
5. Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I. Alpha 1-adrenoceptor pharmacome: alpha 1L-adrenoceptor and alpha 1A-adrenoceptor in the lower urinary tract. Int J Urol 2010;17:31-7. doi:10.1111/j.1442-2042.2009.02368.x
6. Cihan A, Kazaz İ O, Yıldırım Ö, et al. Changing aspects of male sexual functions accompanying treatment of benign prostatic hyperplasia with silodosin 8 mg per day. J Sex Med 2020;17:1094-100. doi:10.1016/j.jsxm.2020.02.023
7. Schilit S, Benzeroual KE. Silodosin: a selective alpha1Aadrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31:2489-502. doi:10.1016/j.clinthera.2009.11.024
8. Miernik A, Gratzke C. Current Treatment for benign prostatic hyperplasia. Dtsch Arztebl Int 2020;117:843-54. doi:10.3238/ arztebl.2020.0843

9. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2017;11:Cd012615. doi:10.1002/14651858. CD012615.pub2
10. Shirwany NA, Zou MH. Arterial stiffness: a brief review. Acta Pharmacol Sin 2010;31:1267-76. doi:10.1038/aps.2010.123
11. Avolio A. Arterial stiffness. Pulse (Basel) 2013;1:14-28. doi:10.1159/000348620
12. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-43. doi:110.1161/01. Atv.0000160548.78317.29
13. Lee GP, Kim HL. Incremental value of the measures of arterial stiffness in cardiovascular risk assessment. Rev Cardiovasc Med 2022;23:6. doi:10.31083/j.rcm2301006
14. Ko YH, Chae JY, Jeong SM, et al. Clinical implications of residual urine in Korean benign prostatic hyperplasia (BPH) patients: A prognostic factor for BPH-related clinical events. Int Neurourol J 2010;14:238-44. doi:10.5213/inj.2010.14.4.238
15. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018. doi:10.1093/ eurheartj/ehae178
16. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043-140. doi:10.1093/ eurheartj/ehad192
17. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025;46:4359-78. doi:10.1093/eurheartj/ehaf190
18. Van Bortel LM, Duprez D, Starmans-Kool MJ, et al. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens 2002;15:445-52. doi:10.1016/s0895-7061(01)02326-3
19. Novara G, Chapple CR, Montorsi F. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int Sep 2014;114:427-33. doi:10.1111/bju.12712
20. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1Aadrenoceptor- selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebocontrolled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. doi:10.1111/j.1464-410X.2006.06448.x
21. Wu YJ, Dong Q, Liu LR, Wei Q. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Prostate Cancer Prostatic Dis 2013;16:79-84. doi:10.1038/pcan.2012.36
22. Manohar CMS, Nagabhushana M, Karthikeyan VS, Sanjay RP, Kamath AJ, Keshavamurthy R. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial. Cent European J Urol 2017;70:148-53. doi:10.5173/ceju.2017.924
23. Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial stiffness and cardiovascular risk in hypertension. Circ Res 2021;128:864-86. doi:10.1161/circresaha.121.318061
24. Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis 2015;238:370-9. doi:10.1016/j. atherosclerosis.2014.12.023
25. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121:505-11. doi:10.1161/ circulationaha.109.886655
26. Schettini IVG, Rios DRA, Figueiredo RC. Effect of different classes of antihypertensive drugs on arterial stiffness. Curr Hypertens Rep 2023;25:61-70. doi:10.1007/s11906-023- 01238-4
27. Wykretowicz A, Guzik P, Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother 2008;9:625-33. doi:10.1517/14656566.9.4.625
28. Komai N, Ohishi M, Moriguchi A, et al. Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002;25:5-10. doi:10.1291/hypres.25.5
29. Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 2011;6:161-72. doi:10.2147/cia.S13803